3,392 Shares in Novo Nordisk A/S (NYSE:NVO) Purchased by Prosperity Consulting Group LLC

Prosperity Consulting Group LLC bought a new stake in Novo Nordisk A/S (NYSE:NVO) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 3,392 shares of the company’s stock, valued at approximately $436,000.

Other hedge funds also recently bought and sold shares of the company. Cravens & Co Advisors LLC raised its position in Novo Nordisk A/S by 1.0% in the first quarter. Cravens & Co Advisors LLC now owns 8,250 shares of the company’s stock worth $1,059,000 after acquiring an additional 85 shares in the last quarter. Sage Rhino Capital LLC increased its holdings in shares of Novo Nordisk A/S by 0.7% in the 1st quarter. Sage Rhino Capital LLC now owns 12,320 shares of the company’s stock valued at $1,582,000 after purchasing an additional 89 shares in the last quarter. U.S. Capital Wealth Advisors LLC lifted its stake in shares of Novo Nordisk A/S by 0.6% in the fourth quarter. U.S. Capital Wealth Advisors LLC now owns 15,421 shares of the company’s stock valued at $1,595,000 after purchasing an additional 90 shares during the period. Clarius Group LLC boosted its holdings in Novo Nordisk A/S by 0.5% during the fourth quarter. Clarius Group LLC now owns 18,505 shares of the company’s stock worth $1,914,000 after buying an additional 93 shares in the last quarter. Finally, Tradewinds Capital Management LLC grew its position in Novo Nordisk A/S by 2.0% during the fourth quarter. Tradewinds Capital Management LLC now owns 4,955 shares of the company’s stock worth $513,000 after buying an additional 95 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 2.5 %

Shares of NVO traded up $3.50 on Friday, hitting $142.37. 3,664,490 shares of the stock traded hands, compared to its average volume of 3,456,442. Novo Nordisk A/S has a 1 year low of $75.56 and a 1 year high of $148.15. The stock’s 50 day moving average is $136.52 and its two-hundred day moving average is $124.87. The firm has a market capitalization of $638.89 billion, a P/E ratio of 49.11, a P/E/G ratio of 1.37 and a beta of 0.41. The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Thursday, May 2nd. The company reported $0.83 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.06. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. The business had revenue of $9.52 billion during the quarter, compared to the consensus estimate of $9.23 billion. As a group, sell-side analysts predict that Novo Nordisk A/S will post 3.44 earnings per share for the current year.

Analysts Set New Price Targets

NVO has been the topic of several research analyst reports. BMO Capital Markets reissued an “outperform” rating and set a $163.00 price target on shares of Novo Nordisk A/S in a research note on Tuesday, June 25th. Argus boosted their target price on Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a research report on Monday, June 10th. The Goldman Sachs Group initiated coverage on Novo Nordisk A/S in a research note on Thursday, May 30th. They set a “buy” rating and a $156.00 price target for the company. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Monday, July 1st. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Moderate Buy” and an average price target of $145.67.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.